Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arhalofenate - CymaBay Therapeutics

Drug Profile

Arhalofenate - CymaBay Therapeutics

Alternative Names: JNJ 39659100; K-118; MBX-102; Metaglidasen

Latest Information Update: 26 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Metabolex
  • Developer CymaBay Therapeutics
  • Class Amides; Anti-inflammatories; Antigouts; Antihyperglycaemics; Insulin sensitisers; Small molecules; Uricosurics
  • Mechanism of Action Peroxisome proliferator-activated receptor gamma agonists; SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gout; Type 2 diabetes mellitus

Most Recent Events

  • 22 Mar 2024 CymaBay Therapeutics has been acquired by Gilead Sciences
  • 12 Jul 2019 Discontinued - Phase-II for Gout (Combination therapy) in Canada, Georgia, USA (PO) (Cymabay Therapeutics pipeline, July 2019)
  • 12 Jul 2019 Discontinued - Phase-II for Gout (Monotherapy) in Canada, Georgia, USA (PO) (Cymabay Therapeutics pipeline, July 2019)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top